Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, noviembre 13
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
10x Genomics Inc
TXG
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$59.10
-2.95
-4.75%
al cierre: Nov 11, 4:00 PM EST
$59.50
-2.55
-4.11%
Premercado: 4:11 AM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
10x Genomics Financials
10x Genomics (TXG) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
10x Genomics Raises FY2026 Sales Guidance from $610.000M-$630.000M to $625.000M-$635.000M vs $619.854M Est
10x Genomics (NASDAQ:TXG) raises FY2026 sales outlook from $610.000 million-$630.000 million to $625.000 million-$635.000 million vs $619.854 million estimate.
Benzinga Newsdesk
PRO
10x Genomics Q3 EPS $(0.15) Beats $(0.25) Estimate, Sales $150.667M Beat $147.859M Estimate
Benzinga Newsdesk
PRO
10x Genomics Raises FY2026 Sales Guidance from $600.000M-$625.000M to $610.000M-$630.000M vs $613.851M Est
10x Genomics (NASDAQ:TXG) raises FY2026 sales outlook from $600.000 million-$625.000 million to $610.000 million-$630.000 million vs $613.851 million estimate.
Benzinga Newsdesk
PRO
10x Genomics Q2 EPS $(0.14) Beats $(0.24) Estimate, Sales $151.000M Beat $146.788M Estimate
10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.24) by 41.67 percent. This is a 150 percent decrease over earnings of $0.28 per share from the
Benzinga Newsdesk
PRO
10x Genomics Affirms FY2026 Sales Guidance of $600.000M-$625.000M vs $613.107M Est.
10x Genomics (NASDAQ:TXG) affirms FY2026 sales outlook from $600.000 million-$625.000 million to $600.000 million-$625.000 million vs $613.107 million estimate.
Benzinga Newsdesk
PRO
10x Genomics Q1 EPS $(0.10) Beats $(0.30) Estimate, Sales $150.843M Beat $146.355M Estimate.
10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.30) by 66.67 percent. This is a 64.29 percent increase over losses of $(0.28) per share from the
Benzinga Newsdesk
